These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19631585)

  • 21. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
    Sharabi A; Azulai H; Sthoeger ZM; Mozes E
    Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triggering of Toll-like receptors modulates IFN-gamma signaling: involvement of serine 727 STAT1 phosphorylation and suppressors of cytokine signaling.
    Dalpke AH; Eckerle S; Frey M; Heeg K
    Eur J Immunol; 2003 Jul; 33(7):1776-87. PubMed ID: 12811837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of interferon-induced Stat1 phosphorylation in activated T cells.
    Van De Wiele CJ; Marino JH; Whetsell ME; Vo SS; Masengale RM; Teague TK
    J Interferon Cytokine Res; 2004 Mar; 24(3):169-78. PubMed ID: 15035850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pravastatin attenuates interferon-gamma action via modulation of STAT1 to prevent aortic atherosclerosis in apolipoprotein E-knockout mice.
    Zhou XX; Gao PJ; Sun BG
    Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):373-9. PubMed ID: 19018808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Cyclin-Dependent Kinase 1 as a Novel Regulator of Type I Interferon Signaling in Systemic Lupus Erythematosus.
    Wu L; Qin Y; Xia S; Dai M; Han X; Wu Y; Zhang X; Ma J; Wang Y; Tang Y; Liu Z; Zhu W; Jallal B; Yao Y; Qu B; Shen N
    Arthritis Rheumatol; 2016 May; 68(5):1222-32. PubMed ID: 26663909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of suppressor of cytokine signaling-1 by Toxoplasma gondii contributes to immune evasion in macrophages by blocking IFN-gamma signaling.
    Zimmermann S; Murray PJ; Heeg K; Dalpke AH
    J Immunol; 2006 Feb; 176(3):1840-7. PubMed ID: 16424215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2 Inhibition Interferes With the Activation of Type I Interferon Signaling Pathway and Ameliorates Lupus Nephritis in NZB/NZW F1 Mice.
    Wu L; Jiang X; Qi C; Zhang C; Qu B; Shen N
    Front Immunol; 2021; 12():653989. PubMed ID: 33868295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
    Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
    J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A role for the B-cell CD74/macrophage migration inhibitory factor pathway in the immunomodulation of systemic lupus erythematosus by a therapeutic tolerogenic peptide.
    Lapter S; Ben-David H; Sharabi A; Zinger H; Telerman A; Gordin M; Leng L; Bucala R; Shachar I; Mozes E
    Immunology; 2011 Jan; 132(1):87-95. PubMed ID: 20738420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the pro-apoptotic factor JNK kinase.
    Rapoport MJ; Sharabi A; Aharoni D; Bloch O; Zinger H; Dayan M; Mozes E
    Clin Immunol; 2005 Dec; 117(3):262-70. PubMed ID: 16257268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Potential for Targeting the Suppressor of Cytokine Signalling-1 Pathway for the Treatment of SLE.
    Sukka-Ganesh B; Larkin J
    Scand J Immunol; 2016 Nov; 84(5):299-309. PubMed ID: 27781323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of tacrolimus on IFN-γ signaling in keratinocytes: possible mechanisms by which tacrolimus affects IFN-γ-dependent skin inflammation.
    Tu HQ; Li XY; Tang MY; Gao JW; Xu LF; Chen ZQ; Gu H
    Eur J Dermatol; 2011; 21(1):22-31. PubMed ID: 21227887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suppressor of cytokine signaling 3 (SOCS-3) protects beta -cells against interleukin-1beta - and interferon-gamma -mediated toxicity.
    Karlsen AE; Rønn SG; Lindberg K; Johannesen J; Galsgaard ED; Pociot F; Nielsen JH; Mandrup-Poulsen T; Nerup J; Billestrup N
    Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12191-6. PubMed ID: 11593036
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations.
    Elmann A; Sharabi A; Dayan M; Zinger H; Ophir R; Mozes E
    Arthritis Rheum; 2007 Jul; 56(7):2371-81. PubMed ID: 17599765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression.
    Miyoshi H; Fujie H; Shintani Y; Tsutsumi T; Shinzawa S; Makuuchi M; Kokudo N; Matsuura Y; Suzuki T; Miyamura T; Moriya K; Koike K
    J Hepatol; 2005 Nov; 43(5):757-63. PubMed ID: 16083990
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostacyclin inhibits IFN-gamma-stimulated cytokine expression by reduced recruitment of CBP/p300 to STAT1 in a SOCS-1-independent manner.
    Strassheim D; Riddle SR; Burke DL; Geraci MW; Stenmark KR
    J Immunol; 2009 Dec; 183(11):6981-8. PubMed ID: 19915063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor.
    Emery B; Butzkueven H; Snell C; Binder M; Kilpatrick TJ
    Neuroscience; 2006; 137(2):463-72. PubMed ID: 16289836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
    Sthoeger Z; Sharabi A; Zinger H; Asher I; Mozes E
    Clin Immunol; 2018 Dec; 197():34-39. PubMed ID: 30170030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo.
    Naka T; Tsutsui H; Fujimoto M; Kawazoe Y; Kohzaki H; Morita Y; Nakagawa R; Narazaki M; Adachi K; Yoshimoto T; Nakanishi K; Kishimoto T
    Immunity; 2001 May; 14(5):535-45. PubMed ID: 11371356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repression of IL-4-induced gene expression by IFN-gamma requires Stat1 activation.
    Venkataraman C; Leung S; Salvekar A; Mano H; Schindler U
    J Immunol; 1999 Apr; 162(7):4053-61. PubMed ID: 10201928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.